KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma

KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma

Abstract The clinical utility of liquid biopsy (LB) for pancreatic ductal adenocarcinoma (PDAC) remain understudied. Our single-institution cohort of 311 PDAC patients with non-tumor tissues informed LB found 81.2% positivity (N = 186) in metastatic cases and in 52.4% (N = 43) of localized disease....

Full description

Saved in:
Bibliographic Details
Main Authors: Mahmoud Yousef, Abdelrahman Yousef, Mark W. Hurd, Ashwathy Pillai, Saikat Chowdhury, Rebecca Snyder, Mark Knafl, Ryan L. Lewis, Paul M. Roy, Mohammad Fanaeian, Sali Albarouki, Luca F. Castelnovo, Jennifer Peterson, Brandon G. Smaglo, Robert A. Wolff, Shubham Pant, Jason Willis, Ryan Huey, Michael Overman, Ching-Wei Tzeng, Michael P. Kim, Naruhiko Ikoma, Jess E. Maxwell, Matthew H. G. Katz, Huamin Wang, Anirban Maitra, Eugene Koay, Ethan B. Ludmir, Anthony Chen, Camila Lopez, Haoqiang Ying, John Paul Shen, Dan Zhao
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Journal of Hematology & Oncology
Subjects:
Pancreatic cancer
Liquid biopsy
KRAS
PDAC
Molecular profiling
Mutation
Online Access:https://doi.org/10.1186/s13045-025-01696-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13045-025-01696-0

Similar Items